



International Scientific Committee

- J.J.M. van Dongen (chair)
- Monika Brüggemann
- Gianni Cazzaniga
- Patricia Groenen
- Jerry Hancock
- Marco Ladetto
- Ton Langerak
- Alberto Orfao
- Thorsten Raff
- Beat Schäfer
- Tomasz Szczepanski
- Jan Trka
- Neus Villamor

Local Organizing Committee

- B. Schäfer
- J.J.M. van Dongen
- W.M. Bitter
- B. van Bodegom
- S. Kubetzko
- B. Beukenkamp

Information and organization

Dept. Immunology
Erasmus MC
Wytemaweg 80
3015 CN Rotterdam
Tel: +31-10-704 31 88
Fax: +31-10-704 47 31
E-mail: w.comans@erasmusmc.nl
b.vanbodegom@erasmusmc.nl

Erasmus MC - het Congresbureau
Bernice Beukenkamp
P.O. Box 2040
3000 CA Rotterdam
Tel: +31-10-703 16 21
Fax: +31-10-704 47 37
E-mail: b.beukenkamp@erasmusmc.nl
www.hetcongresbureau.nl

General information

Date
5-6 November 2015

Venue
World Trade Center
Leutschenbachstrasse 95
8050 Zürich
Switzerland

Registration and Information
For more information, accommodation and registration please check the website: www.hetcongresbureau.nl (congresagenda).

Registration fee (including Conference Dinner): € 250,-

Abstracts

Submission of abstracts related to the four MRD sessions is strongly encouraged.
Up to 10 abstracts will be selected for oral presentations.
Up to 20 abstracts will be selected for poster presentation.

Deadline for submission: August 28, 2015
Selection of abstracts: before end of September 2015

Scientific Working Group of:



EuroMRD



EuroClonality

EuroFlow

www.ESLHO.org



4th ESLHO Symposium
New Developments in
MRD diagnostics

5-6 November 2015
World Trade Center, Zürich, Switzerland

Thursday, 5 November 2015

12:00 – 13:00	Registration and Lunch
13:00 – 13:10	Welcome – Beat Schäfer and Jacques J.M. van Dongen
13:10 – 15:00	Session 1: MRD Technologies <i>Chair: Beat Schäfer and Jerry Hancock</i> - MRD Concept and overview MRD technologies <i>Jacques J.M. van Dongen, Rotterdam, NL (25 min)</i> - New developments in MRD detection via NGS <i>Monika Brüggemann, Kiel, DE (25 min)</i> - New developments in flow cytometric MRD detection <i>Alberto Orfao, Salamanca, ES (25 min)</i> 2 abstract-based oral presentations (each 10 min)
15:00 – 15:30	Coffee/Tea
15:30 – 17:30	Session 2: MRD in BCP-ALL <i>Chair: Jan Trka and Tomasz Szczepanski</i> - MRD in the standard and experimental treatment of childhood ALL <i>Martin Schrappe, Kiel, DE (25 min)</i> - MRD persistence in adult ALL - concepts to overcome treatment <i>Renato Bassan, Venice, IT (25 min)</i> - MRD in the era of targeted treatments: an end-point or a predictive factor? <i>Maria Grazia Valsecchi, Monza, IT (25 min)</i> 2 abstract-based oral presentations (each 10 min)
17:30 – 17:45	Short break
17:45 – 18:45	Keynote Lectures: <i>Chair: Marco Ladetto</i> - MRD diagnostics in lymphoma <i>Christiane Pott, Kiel, DE (30 min)</i> 2 abstract-based oral presentations (each 10 min)
19:30 – 23:00	<i>Dinner (free for all registered participants)</i>

Friday, 6 November 2015

08:00 – 10:00	Session 3: MRD in CLL <i>Chair: Neus Villamor and Ton Langerak</i> - Flow cytometric versus PCR MRD in CLL <i>Matthias Ritgen, Kiel (25 min)</i> - MRD diagnostics as primary endpoint in CLL <i>Speaker to be confirmed (25 min)</i> - MRD diagnostics in the context of SCT in CLL patients <i>Michel van Gelder, Maastricht, NL (25 min)</i> 2 abstract-based oral presentations (each 10 min)
10:00 – 10:30	Coffee
10:30 – 12:15	Session 4: MRD in Multiple myeloma <i>Chair: Brian Durie and Alberto Orfao</i> - Introduction: MRD monitoring in the treatment of MM <i>Brian Durie, Los Angeles, USA (10 min)</i> - Monitoring of MRD in multiple myeloma: how feasible is it? <i>Ola Landgren, New York, USA (25 min)</i> - The role of MRD in redefining remission in MM <i>Bruno Paiva, Pamplona, ES (25 min)</i> - Antibody-based therapy in MM <i>Philippe Moreau, Nantes, FR (25 min)</i> 1 abstract-based oral presentation (10 min)
12:15 – 12:45	Round Table Discussion <i>Moderator: Jacques J.M. van Dongen</i> <i>Participants: Maria Grazia Valsecchi, Martin Schrappe, Brian Durie, Ola Landgren and Philippe Moreau</i> <i>Topics: - MRD as primary endpoint: what is needed?</i> <i>- Which MRD Technology will be preferred in five years from now</i>
12:45 – 13:00	Closing Remarks
13:00 – 14:00	Lunch